

Clinical Trial Protocol

Iranian Registry of Clinical Trials

12 Jun 2026

The protective Potential of resveratrol in the prevention and reduction of complications in patients undergoing elective coronary artery bypass grafting surgery

Protocol summary

Study aim

The aim of this study is to evaluate the protective Potential of resveratrol in the prevention and reduction of complications in patients undergoing elective coronary artery bypass grafting surgery

Design

In the form of clinical trial, double blinded study

Settings and conduct

The Heart Center, affiliated to Bushehr University of Medical Sciences, Iran

Participants/Inclusion and exclusion criteria

, Inclusion criteria: Intention of the patients to participate in the trial, patients on elective surgery, having no addiction to any drugs or alcohol, mental or psychological disorders and the age between 30 to 70 years. Exclusion criteria: history of having chronic kidney or liver disease, having heart surgery before

Intervention groups

Th the case group 250 mg capsules of resveratrol, two times a day for 60 days will be given. The control group will be without resveratrol.

Main outcome variables

Heart Function, including: Ejection Fraction, left ventricular function, ECG, blood pressure(diastolic and Systolic).

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20111119008129N12**

Registration date: **2022-06-18, 1401/03/28**

Registration timing: **prospective**

Last update: **2022-06-18, 1401/03/28**

Update count: **0**

Registration date

2022-06-18, 1401/03/28

Registrant information

Name

Ali Movahed

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 77 3332 4044

Email address

a.movahed@bpums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-06-20, 1401/03/30

Expected recruitment end date

2022-12-21, 1401/09/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The protective Potential of resveratrol in the prevention and reduction of complications in patients undergoing elective coronary artery bypass grafting surgery

Public title

Protective role of Resveratrol in Heart surgery

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria:

Intention of the patients to participate in the trial
Patients on elective surgery Having no addiction to any drugs or alcohol Not having mental or psychological disorders Participants with the age between 30 to 70 years

Exclusion criteria:

History of having chronic kidney disease, History of having chronic liver disease Having heart surgery before

Age

From **30 years** old to **70 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser

Sample size

Target sample size: **60**

More than 1 sample in each individual

Number of samples in each individual: **2**

The samples will be collected before and after the trial

Randomization (investigator's opinion)

Randomized

Randomization description

The random allocation method in this study will be permuted block randomization, where T represents the person receiving the intervention and C represents the person who receive the Placebo. This method is performed by considering blocks of sizes 4 patients so that the total number of 4 permutations is equal to 6 blocks as follows: (C,C,T,T), (T,T,C,C), (C,T,T,C), (C,T,C,T), (T,C,C,T), (T,C,T,C), (C,T,C,T) Then, a number of 15 blocks will be randomly selected with replacement from these 6 blocks. Finally, the desired list of 15 blocks of 4 ($4 * 15 = 60$ total number of samples) is generated and the order of assignment to each of the samples participating in the study is determined. These steps are performed using R software version 3.6.3

Blinding (investigator's opinion)

Double blinded

Blinding description

First, all resveratrol and placebo capsules are prepared in the same shape and size and in packs of 20 for distribution to patients. The resveratrol and placebo packages are then labeled based on computer-generated codes (without indication of its content). Each of these codes is determined based on the sequence of random allocation of individuals to groups. The project manager, the only person who is aware of the codes and the order in which individuals are assigned to groups, is not involved in any of the evaluation and measurement of outcomes steps. On the other hand, the shape, size, and type of packaging of the resveratrol and placebo are exactly the same, so the patient and the outcome evaluator will not know the type of intervention.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Bushehr University of Medical Sciences, Bushehr, Iran

Street address

Moallem Street, Bushehr Medical University

City

Bushehr

Province

Boushehr

Postal code

987514633341

Approval date

2022-04-25, 1401/02/05

Ethics committee reference number

IR.BPUMS.REC.1401.024

Health conditions studied

1

Description of health condition studied

Diseases of the circulatory system

ICD-10 code

I24

ICD-10 code description

Ischemic heart diseases

Primary outcomes

1

Description

The heart function

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 12 to 24 hours after the period of 60 days of consumption

Method of measurement

By echocardiography

2

Description

Diastolic blood pressure

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 12 to 24 hours after the period of 60 days of consumption

Method of measurement

By sphygmomanometer, Mercury Type (Microlife

company)

3

Description

systolic blood pressure

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 12 to 24 hours after the period of 60 days of consumption

Method of measurement

By sphygmomanometer, Mercury Type (Microlife company)

Secondary outcomes

1

Description

Total Antioxidant Capacity(TAC)

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 24 to 72 hours after the period of 60 days of Resveratrol consumption

Method of measurement

By ELISA technique

2

Description

LDH (lactate dehydrogenase)

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 24 to 72 hours after the period of 60 days of Resveratrol consumption

Method of measurement

By reliable kits(By using spectrophotometry)

3

Description

TBRS

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 24 to 72 hours after the period of 60 days of Resveratrol consumption

Method of measurement

By ELISA technique

4

Description

CK-MB (creatine kinase MB)

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 24 to 72 hours after the period of 60 days of Resveratrol consumption

Method of measurement

By reliable kits(By using spectrophotometry)

5

Description

NO (Nitric oxide)

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 24 to 72 hours after the period of 60 days of Resveratrol consumption

Method of measurement

By ELISA technique

6

Description

TNF- α (tumor necrosis factor- α)

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 24 to 72 hours after the period of 60 days of Resveratrol consumption

Method of measurement

By ELISA technique

7

Description

hs-CRP (High-sensitivity C-reactive Protein)

Timepoint

Around 24 hours, before the start of Resveratrol consumption, and 24 to 72 hours after the period of 60 days of Resveratrol consumption

Method of measurement

By reliable kits(By using spectrophotometry)

Intervention groups

1

Description

Intervention group: To this group will be given 250 mg capsules of Resveratrol (98% pure, AllNatural, Nutritional INC, Winnipeg, Canada). two times a day, morning and evening for a period of 60 days.

Category

Prevention

2

Description

Control group: To this group, will be given 250 mg capsules of totally inert -microcellulose, Biotivia, Bioceuticals International Srl, Italy) and the routine medicines. And, all the examinations for heart function and blood examinations are done, exactly in the same way as the intervention group. Before and after the Trial.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

The Bushehr Heart Center, affiliated to Bushehr University of Medical Sciences, Bushehr, Iran

Full name of responsible person

Ali Movahed

Street address

Moallem Street, Bushehr Heart Center,

City

Bushehr

Province

Boushehr

Postal code

987514633341

Phone

+98 917 371 1063

Email

a.movahed@BPUMS.AC.IR

Full name of responsible person

Ali Movahed

Position

Academic Member

Latest degree

Ph.D.

Other areas of specialty/work

Biochemistry

Street address

Moallem ST, Faculty of Medicine, Biochemistry Laboratory, Bushehr University Of Medical Sciences, Bushehr, Iran.

City

Bushehr

Province

Boushehr

Postal code

987514633341

Phone

+98 77 3332 4044

Email

a.movahed@BPUMS.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Boushehr University of Medical Sciences

Full name of responsible person

Akram Farhadi

Street address

Bushehr University of Medical Sciences, Department of Research, Salmon Farsi Street, Bahmani, Bushehr, Iran.

City

Bushehr

Province

Boushehr

Postal code

987518759577

Phone

+98 77 3345 0178

Email

Research@BPUMS.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Boushehr University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Boushehr University of Medical Sciences

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Boushehr University of Medical Sciences

Full name of responsible person

Ali Movahed

Position

Academic Member,

Latest degree

Ph.D.

Other areas of specialty/work

Biochemistry

Street address

Moallem ST, Faculty of Medicine, Biochemistry Lab, Bushehr University of Medical Sciences, Bushehr, Iran

City

Bushehr

Province

Boushehr

Postal code

987514633341

Phone

+98 77 3332 4044

Email

a.movahed@BPUMS.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Boushehr University of Medical Sciences

Full name of responsible person

Ali Movahed

Position

Academic Member

Latest degree

Ph.D.

Other areas of specialty/work

Biochemistry

Street address

Biochemistry Lab, Faculty of Medicine, Bushehr
University of Medical Sciences, Moallem ST, Bushehr,
Iran

City

Bushehr

Province

Boushehr

Postal code

987514633341

Phone

+98 77 3332 4044

Email

a.movahed@BPUMS.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available

Title and more details about the data/document

The Deputy of Research is responsible to provide the information and documents to the participants in the Trial.

When the data will become available and for how long

After the trial was over and the results were analyzed, for a period of one year, access to the document is possible.

To whom data/document is available

The principal investigator, the participants undergone the trial, deputy of research and technology.

Under which criteria data/document could be used

1- If the researcher wants the document to use in the following research. 2- The patients who want to know about the results of the examination

From where data/document is obtainable

The main investigator or responsible for the trial, or the deputy of Research should be contacted.

What processes are involved for a request to access data/document

A request letter to be given to the main investigator, or the Deputy of Research to be consider.

Comments